UK Warehouse Hepatitis C Virus Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

China UK Warehouse Hepatitis C Virus Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0, Find details about China Sofosbuvir, 1190307-88-0 from UK Warehouse Hepatitis C Virus Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

Basic Info.

Model NO.

Sofosbuvir

CAS

1190307-88-0

C22h29fn3o9p

Einecs

695-717-4

Appearance

White Powder

Shelf Life

2 Years

Storage

Cool Dry Place

Deliver Time

7-10days

Trademark

Biocar

Transport Package

Bag or Drum

Specification

1kg/Bag; 25kg/Drum

Origin

Wuhan China

HS Code

2942000000

Model NO.

Sofosbuvir

CAS

1190307-88-0

C22h29fn3o9p

Einecs

695-717-4

Appearance

White Powder

Shelf Life

2 Years

Storage

Cool Dry Place

Deliver Time

7-10days

Trademark

Biocar

Transport Package

Bag or Drum

Specification

1kg/Bag; 25kg/Drum

Origin

Wuhan China

HS Code

2942000000

Product Desciption

UK Warehouse Hepatitis C Virus Sofosbuvir/Daclatasvir/Ledipasvir 1190307-88-0

Basic Information

Product Name	1190307-88-0
Appearance	White powder
Assay	99%min
Test	HPLC
Certificate	ISO 9001
CAS	1190307-88-0
MF	C22H29FN3O9P
Storage Temperature	Cool Dry Place

Description

Sofosbuvir is first without joint interferon can be safe and effective drug for the treatment of
certain types of hepatitis c.Clinical trials confirm for type 1 and 4 c, the drug combination of
polyethylene glycol (peg) interferon and ribavirin overall sustained virological response (SVR)
is as high as 90%;In view of the type 2 c, the drug plus ribavirin SVR is 89% - 95%;In view
of the 3 c, the drug plus ribavirin SVR is 61% - 63%.

is drug used in combination with other drugs to treat hepatitis C (HCV). The other drugs used
in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus
genotype and whether the person has cirrhosis.

Function

sofosbuvir is a kind of hepatitis c virus (HCV) NS5B polymerase inhibitors nucleotide analogues, applicable to as united antiviral treatment composition in the treatment of chronic hepatitis c (CHC) infection.
sofosbuvir confirmed by test can effectively treat genotype 1, 2, 3, or 4 c subjects, including within milan criteria are awaiting liver transplantation of HCC subjects and co-infection of HCV/HIV - 1 subjects.

COA

Batch No.	HF150920	Quantity	850gs
Mfg. Date	Sep. 20, 2015	Package	As required
Rep. Date	Sep. 24, 2015	Exp. Date	Sep. 19, 2017
Items	Standards		Results
Appearance	White to off-white solid powder		Complies
Identification	By IR		Complies
	By HPLC		Complies
Solubility(1% H2O)	Colorless to faint yellow		Complies
Water Content	≤8.0%		5.8%
Related Substance	Any Unknown Individual Impurity: ≤1.50%		Complies
	Total Impurities: ≤3.00%		2.5%
Assay (HPLC basis on drying)	97.0%~101.5%		97.5%
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool place